This month, Hannah and Mike speak to Pierre van Weperen, CEO of Grow Pharma, a joint venture between GROW Group and IPS Pharma in the UK.

Pierre joined GROW Group in 2019, with more than 30 years experience in the pharmaceutical industry, which took him from his home in the Netherlands, to Germany, France and eventually the UK, where he has called home since 2007.

Starting out as a medical rep in the 1990s, Pierre has held senior sales, marketing and leadership roles in a number of top 10 global pharmaceutical companies. Before joining GROW, he managed commercial services for Ashfield Healthcare (the UK’s largest pharmaceutical outsourcing provider) which where he started working with medical cannabis in early 2019.

In this candid interview, Pierre speaks openly about how his personal struggles have given a sense of optimism and a drive to improve things in everything he does, whether that’s for his own loved ones or patients more generally. That is also why he is chairman of the board of the Dutch MS patient association.

He speaks about how this inspires GROW’s focus on the patients who can benefit from medical cannabis and the work by his team to drive awareness, lobby for regulatory changes, and source the best products and innovations for patients and prescribers.

A quick thank you to our sponsors:

This episode What’s Your Why podcast is sponsored by Curaleaf Laboratories.

Curaleaf Laboratories are the UK-leading experts in the manufacture and distribution of EU-GMP medical cannabis as part of Curaleaf International, the biggest cannabis company in the world.

In 2019, Rokshaw joined the Curaleaf International group and because of this, in August 2020, became the first manufacturer of full spectrum medical cannabis in the UK. We aligned with the Curaleaf mission, to provide wider access and unlock the potential of medical cannabis to those who need it.

With over a decade of experience in unlicensed medicines (Specials), Curaleaf have invested heavily in our state-of-the-art UK manufacturing facility, making us perfectly positioned with our international vertically integrated supply chain to deliver cannabis-based medicinal products (CBPM’s) of the highest quality for specialists to prescribe to their patients.

Curaleaf’s wealth of medical cannabis experience, combined with a network of supply and distribution partnerships throughout Europe and the UK, mean that it is uniquely positioned to meet the rapidly growing demand for cost-effective, consistent, premium quality medical cannabis products in the UK.

Find out more at curaleaflaboratories.co.uk

Hosted on Acast. See acast.com/privacy for more information.